Table 3.
The relationship between rLTL and rapid decline in renal function
| Variable | Model 1a | Model 2b | Model 3c | Model 4d | Model 5e | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | |
| Intercept | 0.93 (0.71, 1.23) | 0.615 | 0.07 (0.04, 0.11) | <0.001 | 0.01 (0.00, 0.02) | <0.001 | 0.03 (0.01, 0.15) | <0.001 | 0.03 (0.01, 0.15) | <0.001 |
| rLTL, ∆∆Ctf | 1.22 (1.15, 1.30) | <0.001 | 1.18 (1.11, 1.25) | <0.001 | 1.15 (1.08, 1.22) | <0.001 | 1.09 (1.02, 1.17) | 0.017 | 1.09 (1.01, 1.17) | 0.024 |
| Age, years | 1.05 (1.04, 1.05) | <0.001 | 1.03 (1.02, 1.04) | <0.001 | 1.02 (1.01, 1.04) | <0.001 | 1.02 (1.01, 1.03) | <0.001 | ||
| Male sex | 1.07 (0.92, 1.24) | 0.37 | 1.18 (1.02, 1.38) | 0.032 | 1.08 (0.90, 1.29) | 0.413 | 1.07 (0.89, 1.28) | 0.466 | ||
| Diabetes duration, years | 1.04 (1.03, 1.05) | <0.001 | 1.01 (1.00, 1.03) | 0.066 | 1.01 (0.99, 1.02) | 0.347 | ||||
| BMI, kg/m2 | 1.01 (0.99, 1.03) | 0.244 | 0.99 (0.97, 1.02) | 0.589 | 1.00 (0.97, 1.02) | 0.700 | ||||
| SBP, mmHg | 1.02 (1.02, 1.03) | <0.001 | 1.02 (1.01, 1.02) | <0.001 | 1.02 (1.01, 1.02) | <0.001 | ||||
| DBP, mmHg | 0.99 (0.98, 1.00) | 0.092 | 0.98 (0.97, 0.99) | 0.003 | 0.98 (0.97, 0.99) | 0.004 | ||||
| HbA1c, % | 1.20 (1.14, 1.26) | <0.001 | 1.18 (1.13, 1.24) | <0.001 | ||||||
| LDL-C, mmol/l | 1.00 (0.91, 1.09) | 0.998 | 1.00 (0.91, 1.09) | 0.919 | ||||||
| Log10 triacylglycerol | 1.23 (0.81, 1.87) | 0.332 | 1.33 (0.87, 2.02) | 0.191 | ||||||
| HDL-C, mmol/l | 0.78 (0.60, 0.99) | 0.045 | 0.79 (0.61, 1.01) | 0.059 | ||||||
| eGFR, ml min−1 [1.73 m]−2 | 0.99 (0.98, 0.99) | <0.001 | 0.99 (0.98, 1.00) | <0.001 | ||||||
| Log10 ACR | 3.99 (3.39, 4.71) | <0.001 | 3.79 (3.21, 4.48) | <0.001 | ||||||
| Retinopathy | 1.35 (1.11, 1.64) | 0.003 | ||||||||
| Neuropathy | 1.38 (1.11, 1.71) | 0.004 | ||||||||
| CVD at baseline | 0.93 (0.71, 1.20) | 0.571 | ||||||||
Rapid renal function decline was defined as >4% decline in eGFR per year
aModel 1: without adjustment
bModel 2: adjusted for age and sex
cModel 3: Model 2 + adjusted for duration of diabetes, BMI, SBP and DBP
dModel 4: Model 3 + adjusted for HbA1c, LDL-C, log10 triacylglycerol, HDL-C, eGFR and log10 ACR
eModel 5: Model 4 + retinopathy, neuropathy and CVD at baseline
f∆∆Ct refers to each ∆∆Ct decrease in rLTL
DBP, diastolic BP; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; rLTL, relative LTL calculated by negative control (water); SBP, systolic BP